MDxHealth completed the acquisition of Oncotype DX GPS from Exact Sciences for $100m.

MDxHealth, a commercial-stage precision diagnostics company, completed the acquisition of Oncotype DX GPS from Exact Sciences, a provider of cancer screening and diagnostic test products, for $100m. "We believe the mdxhealth team is well positioned to serve patients and customers in the urology space. Adding the Oncotype DX GPS test and technology to their comprehensive urology test menu will provide an enhanced experience and more information to help patients and health care providers navigate a prostate cancer diagnosis," Kevin Conroy, Exact Sciences Chairman and CEO.